Syndax Pharmaceuticals Inc (SNDX) stock
Close on Nov 13, 2026Market cap $843.86MP/E –Yield –
Syndax Pharmaceuticals Inc grew revenue 159.7% to $289.68M over the twelve months to Sep 30, 2026. Free cash flow was -$323.17M. At the latest close the market valued the company at $843.86M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $843.86M
- P/E ratio
- –
- Price to sales
- 2.91
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $289.68M
- Net income
- -$209.48M
- EPS, diluted
- -$2.36
- Free cash flow
- -$323.17M
- Book value per share
- -$0.19
- Diluted shares
- 90M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $9.54
- Open
- $9.72
- Day's range
- $9.11 – $9.85
- Volume
- 3,179,737
- Average volume (20 days)
- 4,007,094
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $9.11 – $25.59
- RSI (14 days)
- 26.2
- Volatility (1 year)
- 57.0%
- Relative volume
- 1.46×
- WACC
- 8.6%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SNDX | S&P 500 | Difference | SNDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.3% | -3.0% | −29.2 pts | ||
| 3 months | -50.5% | -2.8% | −47.7 pts | ||
| Year to date | -55.0% | +11.5% | −66.5 pts | ||
| 1 year | -43.3% | +13.5% | −56.7 pts | ||
| 3 years | -31.8% | +77.7% | −109.5 pts | -12.0% | +21.1% |
| 5 years | -47.3% | +72.6% | −119.9 pts | -12.0% | +11.5% |
| 10 years | -9.5% | +308.2% | −317.6 pts | -1.0% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Syndax Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Syndax Pharmaceuticals
Pharmaceutical Preparations
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for cancer and immunological conditions. Its approved therapies include revumenib, an oral menin inhibitor for patients with genetically defined acute leukemias, and axatilimab, a targeted antibody for patients with refractory chronic graft-versus-host disease. The company also evaluates these compounds across additional clinical indications, including myelofibrosis and idiopathic pulmonary fibrosis. Its end users are pediatric and adult patients receiving specialized hematology and oncology care.
Company profile, executives and historySyndax Pharmaceuticals stock: common questions
What is Syndax Pharmaceuticals's stock price?
SNDX closed at $9.45 on Nov 13, 2026, down 0.94% on the day. Over the past 52 weeks it traded between $9.11 and $25.59.
What is Syndax Pharmaceuticals's market cap?
Syndax Pharmaceuticals was worth $843.86M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SNDX's P/E ratio?
Syndax Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.36), so it has no meaningful P/E ratio.
How much revenue does Syndax Pharmaceuticals make?
Syndax Pharmaceuticals reported revenue of $289.68M for the twelve months to Sep 30, 2026, up 159.7% from a year earlier.
Does Syndax Pharmaceuticals pay a dividend?
No. Syndax Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Syndax Pharmaceuticals report earnings next?
Syndax Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has SNDX stock performed over the past year?
Including dividends, SNDX returned -43.3% over the past year, against +13.5% for the S&P 500.
How many SNDX shares are sold short?
19M shares were sold short at the latest FINRA report, 21.58% of the float, or 6.4 days of average trading volume.
Who are Syndax Pharmaceuticals's competitors?
Companies most similar to Syndax Pharmaceuticals by business, industry and size include RIGL, IDYA, ZLAB, PBYI, KURA.
See a number that looks wrong?